{"id":9309,"date":"2020-05-07T18:34:02","date_gmt":"2020-05-07T13:04:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9309"},"modified":"2023-02-10T12:04:50","modified_gmt":"2023-02-10T06:34:50","slug":"recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly","title":{"rendered":"Avrobio taps Magenta\u2019s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight pandemic,"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a021dd9f07dd\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a021dd9f07dd\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly\/#Avrobio_taps_ADC_of_Magenta_for_enhancing_gene_therapy_conditioning\" >Avrobio taps ADC of Magenta for enhancing gene therapy conditioning<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly\/#Eli_Lilly_ramps_up_to_combat_the_virus_with_neutralizing_antibodies\" >Eli Lilly ramps up to combat the virus with neutralizing antibodies&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly\/#FDA_postpones_decision_on_approval_of_CAR-T\" >FDA postpones decision on approval of CAR-T<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly\/#CSL_Behring_gears_up_to_fight_pandemic_through_R_D\" >CSL Behring gears up to fight pandemic through R&amp;D&nbsp;&nbsp;&nbsp;&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-avrobio-taps-adc-of-magenta-for-enhancing-gene-therapy-conditioning\"><span class=\"ez-toc-section\" id=\"Avrobio_taps_ADC_of_Magenta_for_enhancing_gene_therapy_conditioning\"><\/span><strong>Avrobio taps ADC of Magenta for enhancing gene therapy conditioning<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to check antibody-drug conjugate.<\/p>\n\n\n\n<p>Under the agreement, the partners will evaluate Magenta\u2019s lead conditioning program, MGTA-117, with at least one of the gene therapies of Avrobio. Each company will have the rights for their respective programs, but Avrobio will pick up for clinical trials, including MGTA-117.<\/p>\n\n\n\n<p>The lead program of Avrobio is a gene therapy for Fabry disease named AVR-RD-01. It is based on CD34+ stem cells, which have been modified utilizing a lentiviral vector to express the gene that codes for the enzyme, which is missing in Fabry disease. It is working on treatments for <a href=\"https:\/\/www.delveinsight.com\/report-store\/gaucher-disease-type-1-market\">Gaucher disease<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/cystinosis-market\">Cystinosis <\/a>and <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\">Pompe disease<\/a> as well.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-eli-lilly-ramps-up-to-combat-the-virus-with-neutralizing-antibodies\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_ramps_up_to_combat_the_virus_with_neutralizing_antibodies\"><\/span><strong>Eli Lilly ramps up to combat the virus with neutralizing antibodies&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Many drug makers are opting to produce neutralizing antibodies, which aim the spike protein on the surface of <a href=\"https:\/\/www.delveinsight.com\/blog\/questions-and-answers-on-coronavirus-covid-19\">SARS-CoV-2<\/a>, which causes the <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a>. Eli Lilly partners with AbCellera to develop neutralizing antibodies to combat the novel coronavirus, Eli Lilly has inked a second partner for defeating the virus.&nbsp; &nbsp;<\/p>\n\n\n\n<p>Eli Lilly has confirmed to reimburse USD 10 million upfront and up to USD 245 million for ex-China rights to co-develop and sell neutralizing antibodies from Junshi Biosciences (China). The lead candidate of Junshi, named as JS016, is a recombinant fully human monoclonal antibody. The pair targets to commence a clinical trial in the U.S.<\/p>\n\n\n\n<p>The agreement marks the latest of at least five other programs focused at developing neutralizing antibodies against the <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">SARS-CoV-2<\/a> spike protein, which binds to the host cell surface receptor ACE2 to aid the virus to enter and affect human cells. The aim is that neutralizing antibodies will be able to prevent that interaction, even if the virus mutates to a more virulent strain.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-postpones-decision-on-approval-of-car-t\"><span class=\"ez-toc-section\" id=\"FDA_postpones_decision_on_approval_of_CAR-T\"><\/span><strong>FDA postpones decision on approval of CAR-T<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has postponed its decision on whether to give a green signal to Bristol Myers Squibb\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-non-hodgkins-lymphoma-market\">CAR-T cell therapy<\/a> by three months. Bristol Myers credited the delay to its submission of additional information upon the request of the FDA.<\/p>\n\n\n\n<p>Lisocabtagene maraleucel, which is also known as liso-cel, is one of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-multiple-myeloma-market\">CAR-T therapies<\/a> that emerged at Juno Therapeutics and ended up at Bristol Myers through its acquisition of Celgene. In February, the FDA granted priority review to a filing for approval of the anti-CD19 <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">CAR-T<\/a>, setting Bristol Myers up to obtain an approval decision from the agency by mid-August.<\/p>\n\n\n\n<p>The FDA has currently thrown that target action date. Instead, the agency is now targeting to decide on whether to approve liso-cel in adults with relapsed or refractory large <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-lymphomas-market\">B-cell lymphoma<\/a> after at least two prior therapies by mid-November.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-csl-behring-gears-up-to-fight-pandemic-through-r-d\"><span class=\"ez-toc-section\" id=\"CSL_Behring_gears_up_to_fight_pandemic_through_R_D\"><\/span><strong>CSL Behring gears up to fight pandemic through R&amp;D&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The largest Australian biotech company CSL said that it is working on a plasma-based therapy for patients with more severe forms of <a href=\"https:\/\/www.delveinsight.com\/blog\/hydroxychloroquine-and-covid-19\">COVID-19<\/a>.<\/p>\n\n\n\n<p>CSL Behring Australia, a subsidiary of CSL Limited, informed regarding that it would commence quick onshore development of an anti-<a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus-2019-ncov-is-now-covid-19\">SARS-CoV-2<\/a> plasma product with the potential for the treatment of people with severe complications of <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\">COVID-19<\/a>, mainly of those whose illness is developing towards the need for ventilation.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The experimental therapy, known as <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a> Immunoglobulin, will be produced by CSL Behring Australia. The giant apprised the need for blood plasma donations from about 800 people that will be collected by the Australian Red Cross, in order for treatment around 100 patients in the trial.<\/p>\n\n\n\n<p>In the first phase of its testing, a small batch of <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">COVID-19<\/a> Immunoglobulin will be made and utilized to develop tests to identify the presence of the antibodies that fight <a href=\"https:\/\/www.delveinsight.com\/blog\/realm-of-pandemics\/\">SARS-CoV-2<\/a>, the virus causing COVID-19.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avrobio taps ADC of Magenta for enhancing gene therapy conditioning Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to check antibody-drug conjugate. Under the agreement, the partners will evaluate Magenta\u2019s lead conditioning program, MGTA-117, with at least one of the gene therapies of Avrobio. Each company will have the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9314,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17884,810,18296,18295,228,254,349,639,489],"industry":[17225],"therapeutic_areas":[17234],"class_list":["post-9309","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-avrobio","tag-car-t","tag-csl-behring","tag-cystinosis","tag-eli-lilly","tag-gaucher-disease","tag-latest-pharma-news","tag-pharma-news","tag-pompe-disease","industry-pharmaceutical","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Avrobio, Magenta, Eli Lilly, CSL Behring, BMS<\/title>\n<meta name=\"description\" content=\"Avrobio taps Magenta\u2019s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight the pandemic with new therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Avrobio, Magenta, Eli Lilly, CSL Behring, BMS\" \/>\n<meta property=\"og:description\" content=\"Avrobio taps Magenta\u2019s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight the pandemic with new therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-07T13:04:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:34:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/07183009\/news-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Avrobio, Magenta, Eli Lilly, CSL Behring, BMS","description":"Avrobio taps Magenta\u2019s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight the pandemic with new therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Avrobio, Magenta, Eli Lilly, CSL Behring, BMS","og_description":"Avrobio taps Magenta\u2019s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight the pandemic with new therapy","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-05-07T13:04:02+00:00","article_modified_time":"2023-02-10T06:34:50+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/07183009\/news-2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly","name":"Pharma News | Avrobio, Magenta, Eli Lilly, CSL Behring, BMS","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/07183009\/news-2.jpg","datePublished":"2020-05-07T13:04:02+00:00","dateModified":"2023-02-10T06:34:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Avrobio taps Magenta\u2019s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight the pandemic with new therapy","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-bms-avrobio-magenta-eli-lilly#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/07183009\/news-2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/07183009\/news-2.jpg","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/07183009\/news-2-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AvroBio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CSL Behring<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cystinosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gaucher disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pompe Disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AvroBio<\/span>","<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">CSL Behring<\/span>","<span class=\"advgb-post-tax-term\">Cystinosis<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Gaucher disease<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pompe Disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 7, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on May 7, 2020 6:34 pm","modified":"Updated on Feb 10, 2023 12:04 pm"},"featured_img_caption":"pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9309"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9309\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9314"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9309"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9309"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}